Effectiveness and feasibility of telerehabilitation in patients with COVID-19: a protocol for a systematic review and meta-analysis.
Effectiveness and feasibility of telerehabilitation in patients with COVID-19: a protocol for a systematic review and meta-analysis.
复制标题
DOI：
10.1136/bmjopen-2021-058932
复制
发表时间：
2022-01-06
期刊：
影响因子：
2.9
通讯作者：
Mohammed AA
中科院分区：
文献类型：
--
作者：
Seid AA;Aychiluhm SB;Mohammed AA
呼吸康复是使用运动，教育和行为干预来缓解症状并改善生活质量。最近的研究强调，呼吸康复对COVID-19患者有效且安全。我们旨在通过进行系统回顾和荟萃分析，评估呼吸远程康复对COVID-19感染患者的有效性和可行性。PubMed、Web of Science、Science Direct、物理治疗证据数据库、Google Scholar和科克伦图书馆数据库将从开始到2021年11月底进行检索。将纳入调查远程康复在COVID-19管理中的有效性的随机对照试验。主要结局将是功能能力、心肺运动试验和生活质量。次要结局将包括焦虑/抑郁水平、睡眠质量、死亡率、完成率、退出原因、不良事件、服务满意度、成本效益和其他潜在因素。两名审查员将独立筛选和提取数据，并对纳入的研究进行质量评估。将使用科克伦偏倚风险工具评估偏倚风险。将使用Review Manager V.5.4（科克伦协作）软件进行统计分析。将使用I²统计分析异质结。将使用平均差异或标准化平均差异以及95% CI和p值计算结局变量的治疗效果。不需要伦理批准，因为本系统性综述和荟萃分析是基于先前发表的数据。最终结果将发表在同行评审的期刊上，并在相关会议和活动中发表。CRD 42021287975。
Respiratory rehabilitation is the use of exercise, education, and behavioural interventions to alleviate symptoms and improve quality of life. Recent studies highlight that respiratory rehabilitation is effective and safe for patients with COVID-19. We aim to evaluate the effectiveness and feasibility of respiratory telerehabilitation on patients infected with COVID-19 by conducting a systematic review and meta-analysis. PubMed, Web of Science, Science Direct, Physiotherapy Evidence Database, Google Scholar and Cochrane Library databases will be searched from inception to the end of November 2021. Randomised controlled trials investigating the effectiveness of telerehabilitation in the management of COVID-19 will be included. The primary outcomes will be functional capacity, cardiopulmonary exercise tests and quality of life. Secondary outcomes will include anxiety/depression level, sleep quality, mortality rate, completion rate, reason for withdrawal, adverse events, service satisfaction, cost-effectiveness and other potential factors. Two reviewers will independently screen and extract data and perform quality assessment of included studies. The Cochrane risk of bias tool will be used to assess risk of bias. Review Manager V.5.4 (Cochrane Collaboration) software will be used for statistical analysis. Heterogeneity will be analysed using I² statistics. Mean difference or standardised mean difference with 95% CI and p value will be used to calculate treatment effect for outcome variables. Ethical approval is not required because this systematic review and meta-analysis is based on previously published data. Final result will be published in peer-reviewed journal and presented at relevant conferences and events. CRD42021287975.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.3390/ijerph18062924
发表时间：
2021-03-12
影响因子：
--
作者：
Pastora-Bernal JM;Estebanez-Pérez MJ;Molina-Torres G;García-López FJ;Sobrino-Sánchez R;Martín-Valero R
通讯作者：
Martín-Valero R
DOI：
10.3390/s21103318
发表时间：
2021-05-11
期刊：
Sensors (Basel, Switzerland)
影响因子：
--
作者：
Bermejo-Gil BM;Pérez-Robledo F;Llamas-Ramos R;Silva LA;Sales-Mendes A;Leithardt VRQ;Llamas-Ramos I
通讯作者：
Llamas-Ramos I
影响因子：
2.9
作者：
Zhu, Feilong;Zhang, Ming;Gao, Min;Zeng, Cheng;Wang, Dan;Hong, Qianqin;Chen, Wei
通讯作者：
Chen, Wei
影响因子：
1.1
作者：
Bairapareddy, Kalyana Chakravarthy;Chandrasekaran, Baskaran;Agarwal, Umang
通讯作者：
Agarwal, Umang